Johnson & Johnson Innovation and Janssen Korea launched the sixth “Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow” in collaboration with the Seoul Metropolitan Government (SMG) and the Korea Health Industry Development Institute (KHIDI).
J&J’s QuickFire Challenge aims to advance breakthrough ideas for potential healthcare solutions by collaborating with SMG to drive innovation and commercialize research outcomes, making the most of KHIDI’s professional systems-building support and Seoul Bio Hub’s ability to accelerate the development and commercialization of early-stage, life-science solutions.
The contest invites global innovators, including individuals, entrepreneurs, academics, biotech researchers, and early-stage companies, to submit their groundbreaking ideas or technologies that can enhance scientific progress across multidisciplinary fields, including oncology, immunology, infectious disease, neuroscience, cardiovascular and metabolic diseases; retinal diseases; and pulmonary hypertension, and vision.
The prizes this year include a grant funding of up to 150 million won ($11,960), two years of residency at the Seoul Bio Hub, access to Johnson & Johnson Innovation’s Asia Pacific ecosystem with a dedicated workstation for one year at JLABS Shanghai, and mentorship from experts across the Johnson & Johnson family of companies.
“Johnson & Johnson Innovation is excited to continue collaborating with SMG and KHIDI on the Seoul Innovation QuickFire Challenge series to address great unmet medical needs as part of Seoul’s growing biomedical ecosystem,” said Melinda Richter, the global head of Johnson & Johnson Innovation. “This year, we’re calling on innovators working across many critical focus areas – from cell therapy to next-generation biosensors to tap into resources within the Korean and broader Asia Pacific ecosystem.”
Cherry Huang, managing director of Janssen North Asia, also said, “We’re excited to continue cultivating the paradigm-shifting scientific innovations such as cell therapy, precision medicine, or AI diagnostics in various therapeutic areas here in Seoul that have the potential to impact patients across the world.”
The deadline for submitting applications is July 15, 2022. More detailed information about the “Seoul Innovation QuickFire Challenge” can be found on the following website: http://jji.jnj/seoul-innovation.